BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 9528995)

  • 1. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models.
    Ke HZ; Paralkar VM; Grasser WA; Crawford DT; Qi H; Simmons HA; Pirie CM; Chidsey-Frink KL; Owen TA; Smock SL; Chen HK; Jee WS; Cameron KO; Rosati RL; Brown TA; Dasilva-Jardine P; Thompson DD
    Endocrinology; 1998 Apr; 139(4):2068-76. PubMed ID: 9528995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats.
    Armamento-Villareal R; Sheikh S; Nawaz A; Napoli N; Mueller C; Halstead LR; Brodt MD; Silva MJ; Galbiati E; Caruso PL; Civelli M; Civitelli R
    J Bone Miner Res; 2005 Dec; 20(12):2178-88. PubMed ID: 16294271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats.
    Ke HZ; Qi H; Chidsey-Frink KL; Crawford DT; Thompson DD
    J Bone Miner Res; 2001 Apr; 16(4):765-73. PubMed ID: 11316005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats.
    Nuttall ME; Bradbeer JN; Stroup GB; Nadeau DP; Hoffman SJ; Zhao H; Rehm S; Gowen M
    Endocrinology; 1998 Dec; 139(12):5224-34. PubMed ID: 9832463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats.
    Ke HZ; Simmons HA; Pirie CM; Crawford DT; Thompson DD
    Endocrinology; 1995 Jun; 136(6):2435-41. PubMed ID: 7750465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat.
    Ke HZ; Qi H; Crawford DT; Chidsey-Frink KL; Simmons HA; Thompson DD
    Endocrinology; 2000 Apr; 141(4):1338-44. PubMed ID: 10746637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of 3-phenyl-4-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]- 2H-1-benzopyran-7-ol (CHF 4056), a novel nonsteroidal estrogen agonist/antagonist, on reproductive and nonreproductive tissue.
    Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
    J Pharmacol Exp Ther; 2002 Mar; 300(3):802-9. PubMed ID: 11861784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model.
    Ke HZ; Chen HK; Simmons HA; Qi H; Crawford DT; Pirie CM; Chidsey-Frink KL; Ma YF; Jee WS; Thompson DD
    Bone; 1997 Jan; 20(1):31-9. PubMed ID: 8988345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.
    Qu Q; Zheng H; Dahllund J; Laine A; Cockcroft N; Peng Z; Koskinen M; Hemminki K; Kangas L; Väänänen K; Härkönen P
    Endocrinology; 2000 Feb; 141(2):809-20. PubMed ID: 10650964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo.
    Sato M; Turner CH; Wang T; Adrian MD; Rowley E; Bryant HU
    J Pharmacol Exp Ther; 1998 Oct; 287(1):1-7. PubMed ID: 9765314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidences for antiosteoporotic and selective estrogen receptor modulator activity of silymarin compared with ethinylestradiol in ovariectomized rats.
    El-Shitany NA; Hegazy S; El-Desoky K
    Phytomedicine; 2010 Feb; 17(2):116-25. PubMed ID: 19577454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of raloxifene on tibia histomorphometry in ovariectomized rats.
    Evans G; Bryant HU; Magee D; Sato M; Turner RT
    Endocrinology; 1994 May; 134(5):2283-8. PubMed ID: 8156931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats.
    Ke HZ; Chen HK; Qi H; Pirie CM; Simmons HA; Ma YF; Jee WS; Thompson DD
    Bone; 1995 Nov; 17(5):491-6. PubMed ID: 8579962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene.
    Rosati RL; Da Silva Jardine P; Cameron KO; Thompson DD; Ke HZ; Toler SM; Brown TA; Pan LC; Ebbinghaus CF; Reinhold AR; Elliott NC; Newhouse BN; Tjoa CM; Sweetnam PM; Cole MJ; Arriola MW; Gauthier JW; Crawford DT; Nickerson DF; Pirie CM; Qi H; Simmons HA; Tkalcevic GT
    J Med Chem; 1998 Jul; 41(16):2928-31. PubMed ID: 9685230
    [No Abstract]   [Full Text] [Related]  

  • 15. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.
    Black LJ; Sato M; Rowley ER; Magee DE; Bekele A; Williams DC; Cullinan GJ; Bendele R; Kauffman RF; Bensch WR
    J Clin Invest; 1994 Jan; 93(1):63-9. PubMed ID: 8282823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats.
    Ke HZ; Foley GL; Simmons HA; Shen V; Thompson DD
    Endocrinology; 2004 Apr; 145(4):1996-2005. PubMed ID: 14726439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the high-affinity estrogen receptor ligand ICI 182,780 on the rat tibia.
    Sibonga JD; Dobnig H; Harden RM; Turner RT
    Endocrinology; 1998 Sep; 139(9):3736-42. PubMed ID: 9724025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in ovariectomized rats.
    Goss PE; Qi S; Cheung AM; Hu H; Mendes M; Pritzker KP
    J Steroid Biochem Mol Biol; 2004 Sep; 92(1-2):79-87. PubMed ID: 15544933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen.
    Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
    J Pharmacol Exp Ther; 2002 Oct; 303(1):196-203. PubMed ID: 12235251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of SP500263, a novel selective estrogen receptor modulator, on bone, uterus, and serum cholesterol in the ovariectomized rat.
    Sutherland MK; Brady H; Gayo-Fung LM; Leisten J; Lipps SG; McKie JA; O'Leary E; Patnaik N; Anderson DW; Bhagwat SS; Stein B
    Calcif Tissue Int; 2003 Jun; 72(6):710-6. PubMed ID: 14563000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.